Uncategorized
Axim, Ora partner on glaucoma, dry eye clinical trials
AXIM Biotechnologies Inc. announced it has retained the services of Ora Inc. to perform the company’s upcoming product development and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics.Ora will run the clinical programs under the supervision of Robert Ritch, MD, surgeon director emeritus and chief of glaucoma services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine.